Last reviewed · How we verify
GenHevac-B
GenHevac-B is a therapeutic hepatitis B vaccine designed to boost immune response in chronically infected patients by presenting hepatitis B surface antigen (HBsAg) to stimulate T-cell and B-cell immunity.
GenHevac-B is a therapeutic hepatitis B vaccine designed to boost immune response in chronically infected patients by presenting hepatitis B surface antigen (HBsAg) to stimulate T-cell and B-cell immunity. Used for Chronic hepatitis B infection (therapeutic vaccination).
At a glance
| Generic name | GenHevac-B |
|---|---|
| Also known as | Sanofi Pasteur MSD |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Therapeutic vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
GenHevac-B uses a recombinant hepatitis B surface antigen formulation to generate or enhance cellular and humoral immune responses in patients with chronic hepatitis B infection. By priming the immune system against HBsAg, the vaccine aims to facilitate viral clearance and functional cure in chronically infected individuals who have failed to mount adequate spontaneous immune responses.
Approved indications
- Chronic hepatitis B infection (therapeutic vaccination)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Low Grade Lymphoma (PHASE4)
- Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST) (PHASE3)
- Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients (PHASE3)
- Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GenHevac-B CI brief — competitive landscape report
- GenHevac-B updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI